Related Experiment Videos
[Basic and clinical studies on tazobactam/piperacillin in pediatric field]
T Motohiro1, K Nagai, T Yamada
1Department of Pediatrics, School of Medicine, Kurume University.
The Japanese Journal of Antibiotics
|October 2, 1998
Summary
The combination drug tazobactam/piperacillin (TAZ/PIPC) demonstrated significant antimicrobial activity against various bacteria, including Streptococcus pyogenes and Haemophilus influenzae. Clinical evaluations showed a high efficacy rate of 93.9% in treating pediatric infectious diseases with minimal adverse effects.
Area of Science:
- Pharmacology and Microbiology
- Clinical Infectious Diseases
- Pediatric Medicine
Background:
- Beta-lactamase inhibitors are crucial in combating antibiotic resistance.
- Piperacillin/tazobactam (TAZ/PIPC) is a combination antibiotic with potential broad-spectrum activity.
- Evaluating the efficacy and safety of TAZ/PIPC in pediatric populations is essential.
Purpose of the Study:
- To assess the in vitro antimicrobial susceptibility of TAZ/PIPC against various bacterial strains.
- To evaluate the clinical efficacy and safety of TAZ/PIPC injection in children with infectious diseases.
Main Methods:
- In vitro susceptibility testing (MIC90) was performed on stock strains and clinical isolates, including Gram-positive cocci and Gram-negative bacilli.
- Clinical efficacy and safety were evaluated in 33 pediatric patients with diverse infectious diseases.
- Bacteriological eradication and adverse reactions were monitored.
Main Results:
- TAZ/PIPC exhibited potent activity against Streptococcus pyogenes and Haemophilus influenzae, with MIC90 values comparable to other tested antibiotics.
- Clinical efficacy was high, with an overall "excellent" or "good" response rate of 93.9% in pediatric patients.
- Bacteriological eradication was achieved in all evaluated strains, and adverse reactions, primarily diarrhea (11.4%), were generally mild.
Conclusions:
- TAZ/PIPC demonstrates significant in vitro antimicrobial activity against key pathogens.
- The combination antibiotic is effective and well-tolerated for treating infectious diseases in children.
- TAZ/PIPC represents a valuable therapeutic option for pediatric infectious disease management.